The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Marketwire

Miraculins Granted U.S. Patent on PreVu(R) Skin Cholesterol Technology

Monday, June 11, 2012

Miraculins Granted U.S. Patent on PreVu(R) Skin Cholesterol Technology07:30 EDT Monday, June 11, 2012WINNIPEG, MANITOBA--(Marketwire - June 11, 2012) -Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent that covers use of spectrophotometric measurements for the non-invasive analysis of skin cholesterol. The allowed patent will cover elements that are key to the PreVu® Non-Invasive Skin Cholesterol Point of Care (POC) Test, specifically relating to the PreVu Handheld Spectrophotometer, which is used to read the level of skin cholesterol during the test."We are pleased with the allowance of this patent which significantly strengthens Miraculins' intellectual property portfolio in the U.S. market. In addition to broadening coverage of the PreVu technology, which is protected by a number of patents and patents pending in North America and internationally, this is another important step towards introducing the PreVu technology into one of the largest markets in the world," stated Christopher J. Moreau, President and Chief Executive Officer of Miraculins Inc. In the U.S., the FDA has directed that "Skin cholesterol as measured by the PreVu POC can be used as part of risk assessment for coronary heart disease in persons with a history of myocardial infarction and/or in persons suspected of having significant multi-vessel coronary artery disease (>50% stenosis in >1 vessel as diagnosed by coronary angiography) where further diagnostic evaluation is being considered. Test results, when considered in conjunction with clinical evaluation, blood cholesterol tests and other risk factors identified for coronary artery disease, will aid the physician in focusing diagnostic and patient management options."Miraculins recently announced the launch of a new English Canadian website for PreVu (www.prevu.com). In addition, the Company has established distribution partnerships for the Canadian medical community and Canadian retail pharmacy market with The Stevens Company and with Pear Healthcare Solutions Inc., respectively. About The PreVu®Non-Invasive Skin Cholesterol TestSkin cholesterol is the cholesterol that has been deposited and diffused into tissue, as opposed to freely circulating in the bloodstream, and has been shown in clinical trials to be strongly associated with significant CAD as measured by treadmill stress testing, coronary angiography, coronary calcium, carotid artery thickening and carotid artery plaque. The PreVu POC Test is completely painless, non-invasive, involves no blood draw or needles, requires no overnight fasting and involves no handling of potentially hazardous biomaterials. It has been developed to provide new and additive information about CAD risk that is independent of traditional risk factors, such as blood cholesterol, to help physicians more effectively assess their patients' risk. The test is conducted on the palm of the hand in less than 5 minutes with results being immediately available.About Miraculins Inc.Miraculins is a medical diagnostic development company focused on acquiring, developing and commercializing non-invasive tests for unmet clinical needs. A significant number of promising diagnostic opportunities remain un-commercialized because of the sizable gap between the discovery stage, when research institutions are typically involved, and the commercialization stage, when the larger commercial enterprises become interested. Miraculins has direct experience in bridging this gap. The Company's PreVu technology is a revolutionary new coronary artery disease risk assessment technology that measures cholesterol levels in a patient's skin non-invasively, painlessly and without the need for fasting. Miraculins is also advancing a suite of biomarkers to aid in the early detection of the devastating disease of pregnancy known as preeclampsia. The Company's preeclampsia program is partnered with Alere, Inc. (NYSE:ALR) (formerly known as Inverness Medical Innovations), one of the world's largest diagnostic companies.For more information on Miraculins please visit www.miraculins.com.Caution Regarding Forward-Looking InformationCertain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins' early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins' filings with Canadian securities regulatory authorities, as well as Miraculins' ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins' forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statement.PreVu®is a registered trademark of Miraculins Inc. All Rights Reserved. 2012.FOR FURTHER INFORMATION PLEASE CONTACT: Christopher J. MoreauMiraculins Inc.President and CEO204-477-7599204-453-1546 (FAX)info@miraculins.comwww.miraculins.comNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.